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Abstract Six new tin(IV) compounds derived from tridentate dinegatively charged ONS 
dithiocarbazate Schiff bases derived from 2-hydroxy-3-methoxybenzaldehyde (H2L1, H2L2 
and H2L3) and 2,3-dihydroxybenzaldehyde (H2L4, H2L5 and H2L6) (where H2Ln = di-acids 
of Schiff base)  are reported. The compounds were characterised by elemental analysis, FT-
IR and multinuclear NMR (
1
H, 
13
C and 
119
Sn) spectroscopy. The crystal structures of tin(IV) 
[S-4-methybenzyl-β-N-(2-hydroxy-3-methoxybenzylmethylene)dithiocarbazate] (2) and 
tin(IV) [S-benzyl-β-N-(2-hydroxy-3-methoxy benzylmethylene)dithiocarbazate] (3) were 
determined by X-ray single crystal diffraction analysis. X-ray crystallography showed the 
molecular geometries in homoleptic 2 and 3 to be quite similar in which the dinegative 
tridentate ligand coordinated the tin atoms via thiolate-S, phenoxide-O and imine-N atoms.  
The coordination geometries are based on an octahedron with like-atoms mutually trans. The 
*Revised Manuscript
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experimental findings were validated by density functional theory (DFT) calculations at the 
B3LYP/LanL2DZ/6-311G(d,p) level of theory. All the tin(IV) compounds, except the 
insoluble compound 2 were screened for their in vitro cytotoxicity against a panel ten of 
cancer cell lines and one normal breast cell line (MCF-10A) by MTT assay. Interestingly, the 
cytotoxicity of five tin(IV) compounds against HT29, MCF7 and MIA was higher than the 
reference drug, cisplatin.  
Keywords tin complex; X-ray crystallography; cytotoxicity 
 
1. Introduction 
Metal ions play an important role in biological systems and are involved in various 
applications, such as cancer therapy and diagnosis of diseases [1]. Metal-based drugs 
including compounds of mercury, copper, gold and arsenic have been used since ancient 
Egyptian, Greek and Chinese societies to treat a broad spectrum of diseases including cancer 
[2–4]. For example, mercury sulphide (cinnabar) was used in the treatment of ailments and 
arsenic trioxide (ATO) for the treatment of rheumatoid diseases, syphilis and psoriasis. In the 
18
th
 century until early 20
th
 century, ATO was among the first group of compounds used in 
the treatment of leukemia, before it was replaced by radiation and chemotherapeutic agents 
[4]. Targeting cancer with chemotherapy after the failure of other therapeutic treatments was 
a valid option due to the effectiveness and action of the chemotherapeutic drugs throughout 
the entire body [5]. In the 1960s, a platinum-based drug, cisplatin was discovered for cancer 
treatments [6] and following its success, the development of platinum drugs flourished, with 
some of them approved as chemotherapeutic drugs. However, platinum-based drugs suffer 
from ineffectiveness in the treatment of platinum-resistant cancers and also have severe side 
effects. Despite the wide use of platinum-based drugs, their biggest challenges - unclear 
therapeutic mechanisms and high toxicity - remain. Hence, the development of improved 
non-platinum-based anticancer drugs became one of the fundamental goals in medicinal 
chemistry. 
There are many possible advantages in using non-platinum-based compounds, such as: (i) a 
variety of coordination sites, (ii) diversity of oxidation states and (iii) affinity and kinetics of 
the bound organic ligands [7–9]. Keeping this in view, tin(IV) compounds have shown a wide 
range of applications and were one of the most in-demand class of organometallic 
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compounds due to their biomedical effectiveness as antifouling, antimicrobial and antiviral 
agents. Saxena and Huber (1989) reported that tin-based compounds were known to localise 
in tumour tissues, hence explaining their effectiveness [10–12]. Since then, tin-based 
compounds have been in the pipeline as potential chemotherapeutic drugs to modulate 
toxicity effects. On top of reduced side effects, tin(IV) compounds exhibited no 
gametogenesis, as cisplatin did, and had increased solubility in water. Tin(IV) compounds 
also did not develop tumour drug resistance which was reported to be the major problem in 
chemotherapy for cisplatin and its analogues towards certain cancer cells [13–15]. Further, 
tin(IV) compounds had potential industrial applications, such as bactericides, fungicides and 
pesticides [16–20].  
Ligand selectivity can be introduced into a system in order to determine their effectiveness in 
bioactivity, particularly in anticancer activity. Ligands not only modify the solubility in lipid 
permeable membranes, but also play a role in transporting and addressing the compound to 
their specific target site [21]. On this note, Schiff bases have long been studied as potential 
target ligands to enhance the bioactivity of chemotherapeutic drugs. Schiff bases can 
coordinate to the tin centre and form stable ligand-tin bonds. Therefore, any modification of 
the structure could modulate the structural diversity and activity of the entire compound [22]. 
A number of reports [23–31] on the complexation of dithiocarbazate Schiff bases have 
received much attention because of their special abilities, including (i) formation of an 
interesting series of ligands where the properties can be greatly modified by introducing 
different types of aldehyde or ketones and (ii) the interaction of donor atoms to the centre 
metal ions creating different geometries and properties, as well as their potential biological 
activities [32]. The number and diversity of applications of tin(IV) compounds, and the 
synthesis and characterisation of tin(IV) compounds containing O-, N-, S- donor Schiff bases 
have been a subject of interest for researchers in the inorganic field, where sulphur is of 
paramount importance in the metal-ligand linkage. The well elucidated structures of the 
Schiff base containing compounds showed interesting biological activities depending on their 
substituents and geometries [33–35].  
In view of all these findings and in continuation of our previously reported research work 
[36] on the chemistry, therapeutic potential and structure-activity relationship of tin(IV) 
compounds coordinated with two dithiocarbazate Schiff bases, we report here the synthesis of 
six new octahedral tin(IV) compounds derived from 2-hydroxy-3-methoxybenzaldehyde and 
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2,3-dihydroxybenzaldehyde dithiocarbazate. The compounds were characterised by FT-IR, 
multinuclear NMR (
1
H, 
13
C and 
119
Sn), mass spectroscopy, UV-vis and density functional 
theory (DFT) calculations. The in vitro cytotoxicity studies were explored and the 
compounds were found to have good activity against the tested cell lines.  
 
2. Experimental Section 
2.1. Materials and Instruments 
All solvents and reagents were of analytical reagent grade and used without further 
purification. Chemicals: hydrazine hydrate, 80% (Fluka), benzylchloride, ≥ 99% (Merck), 2-
methybenzyl chloride, 99% (ACROS), 4-methylbenzyl chloride (ACROS), potassium 
hydroxide (HmbG), carbon disulphide (Merck), 2-hydroxy-3-methoxybenzaldehyde (Merck), 
tin(II) dichloride, 97% (Merck), trimethylamine and > 99% (Sigma Aldrich). Solvents: 
acetonitrile (Baker), absolute ethanol, 99.8% (Scharlau), ethanol, 95% (J. Kollin Chemical), 
methanol (Fisher Scientific) and dimethylsulfoxide (Scharlau). Melting points were 
determined using an Electrothermal digital melting point apparatus. C, H and N elemental 
analyses were carried out using a LECO CHNS-932 instrument and Thermo Flash EA110 
elemental analyser. FT-IR spectra were recorded using PerkinElmer Spectrum 100 with 
Universal ATR Polarization in the range of 4000–280 cm-1 at room temperature. Molar 
conductivities of 10
−3
 M solutions of the metal complexes in DMSO were measured at 27 °C 
using a Jenway 4310 conductivity meter and a dip-type cell with a platinized electrode. 
Electronic spectra were recorded on a Shimadzu UV-2501 PC recording spectrophotometer 
(1000–200 nm). Multinuclear (1H and 13C) Nuclear Magnetic Resonance (NMR) 
spectroscopic analyses were recorded using NMR JNM ECA400 spectrometer. 
119
Sn NMR 
were measured using a Bruker BioSpin Avance III (600 MHz) spectrometer. 
2.2. Synthesis 
2.2.1. Synthesis of Schiff bases 
Schiff bases were synthesised following references [37,36]. Dithiocarbazate (S-2-
methylbenzyldithiocarbazate, S-4-methylbenzyldithiocarbazate or S-benzyldithiocarbazate) 
(10 mmol) was dissolved in hot acetonitrile or ethanol (100 cm
3
) and added to an equimolar 
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amount of 2-hydroxy-3-methoxybenzaldehyde (1.52 g) or 2,3-dihydroxybenzaldehyde (1.38 
g) in absolute ethanol (20 cm
3
). The mixture was heated (80 °C) with continuous stirring for 
about 30 min and then allowed to stand overnight at room temperature. The resultant product 
was recrystallised from CH3CN/EtOH (1:1) to give a light-yellow crystalline solid that was 
filtered and washed with cold absolute ethanol. 
 
2.2.2. Synthesis of tin(IV) compounds (1-3) 
 The Schiff base (0.35 g (H2L1, H2L2); 0.33 g (H2L3, H2L4, H2L5); 0.32g (H2L6), 1 
mmol) was dissolved in absolute ethanol (50 cm
3
) and dichloromethane (20 cm
3
) and was 
mixed with an ethanolic solution (2 mmol) of triethylamine. With continuous stirring, an 
ethanolic solution of SnCl2 (0.20 g, 1 mmol) was added to the mixture. A cloudy solution 
formed which was filtered. The yellow filtrate was then heated under reflux for ca 6 h. The 
mixture was left overnight and the reduction of the volume of the reaction mixture resulted in 
an orange precipitate, which was filtered off. The precipitate was recrystallised in dry ether to 
remove the remaining triethylamine hydrochloride salt from the mixture. 
2.2.2.1. Tin(IV) [S-2-methylbenzyl-β-N-(2-hydroxy-3-methoxybenzylmethylene) 
dithiocarbazate] (1) 
 Orange solid. Yield: 82%. Melting point: >300°C. Analysis calculated for 
C34H32N4O4S4Sn: C, 50.56; H, 3.99; N, 6.94%. Found: C, 50.87; H, 3.58; N, 5.27%. FT-IR 
(ATR, cm
-1
): 1587, v(C=N); 1088, v(N-N); 955, v(C-S). 
1
H NMR (CDCl3) δ (ppm.): 8.81, 
8.45 (s, 2H, CH), 6.77-7.32 (multiplet, 14H, Ar-H), 4.35, 4.47 (s, 4H, CH2), 3.57, 3.85 (s, 6H, 
O-CH3), 2.40, 2.36 (s, 6H, CH3); 
13
C NMR (CDCl3) δ (ppm.): 177.2, 171.0 (C-S), 165.4, 
161.7 (C=N); 115.2, 117.2, 118.4, 119.0, 120.2, 121.9, 126.1, 126.2, 126.4, 126.7, 127.6, 
128.0, 130.4, 130.4, 130.5, 130.6, 133.5, 134.5, 137.2, 137.3, 147.6, 150.4, 152.0, 156.7 
(aromatic-C), 55.3, 56.9 (O-CH3), 36.2, 34.0 (CH2), 19.4 (CH3),.
119
Sn NMR (CDCl3) δ 
(ppm.): -446.  
2.2.2.2. Tin(IV) [S-4-methybenzyl-β-N-(2-hydroxy-3-methoxybenzylmethylene) 
dithiocarbazate] (2) 
 Orange crystals. Yield: 87%. Melting point: 211-214°C. Analysis calculated for 
C34H32N4O4S4Sn: C, 51.56; H, 3.99; N, 6.94%. Found: C, 51.89; H, 4.22; N, 6.53%. FT-IR 
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(ATR, cm
-1
): 1593, v(C=N); 1083, v(N-N); 958, v(C=S). 
1
H NMR (CDCl3) δ (ppm.): 8.77, (s, 
2H, CH), 6.76-7.24 (multiplet, 14H, Ar-H), 4.36 (s, 4H, CH2), 3.56 (s, 6H, O-CH3), 2.33 (s, 
6H, CH3); 
13
C NMR (CDCl3) δ (ppm.): 170.8 (C-S), 165.4 (C=N); 117.2, 118.4, 119.0, 126.7, 
129.2, 129.4, 133.1, 137.3, 152.0, 156.7 (aromatic-C), 56.9 (O-CH3), 35.5 (CH2), 21.2 (CH3). 
119
Sn NMR (CDCl3) δ (ppm.): -446.  
2.2.2.3. Tin(IV) [S-benzyl-β-N-(2-hydroxy-3-methoxybenzylmethylene)dithiocarbazate] (3) 
 Orange crystals. Yield: 53%. Melting point: >300°C. Analysis calculated for 
C32H28N4O4S4Sn: C, 49.30; H, 3.62; N, 7.19%. Found: C, 49.26; H, 3.26; N, 6.02 %. FT-IR 
(ATR, cm
-1
): 1582, v(C=N); 1031, v(N-N); 958, v(C-S). 
1
H NMR (CDCl3) δ (ppm.): 8.78 (s, 
2H, CH), 6.76-7.36 (multiplet, 16H, Ar-H), 4.44 (s, 4H, CH2), 3.55 (s, 6H, O-CH3); 
13
C NMR 
(CDCl3) δ (ppm.): 170.7 (C-S), 165.5 (C=N); 117.2, 118.4, 119.0, 126.7, 127.6, 128.7, 129.3, 
136.3, 152.0, 156.9 (aromatic-C), 56.9 (CH3), 35.7 (CH2).
119
Sn NMR (CDCl3) δ (ppm.): -
447.  
2.2.2.4. Tin(IV)[S-2-methylbenzyl-β-N-(2,3-dihydroxybenzylmethylene) 
dithiocarbazate] (4) 
 Orange powder. Yield: 40%. Melting point: 188-192 °C. Analysis calculated for 
C32H28N4O4S4Sn: C, 49.30; H, 3.62; N, 7.19%. Found: C, 49.14; H, 3.43; N, 7.50%. FT-IR 
(ATR, cm
-1
): 1610, v(C=N); 1035, v(N-N); 964, v(C-S). 
1
H NMR (CDCl3) δ (ppm.) : 8.90 (s, 
2H, CH), 6.02-7.34 (multiplet, 14H, Ar-H), 4.48 (s, 4H, CH2), 2.42 (s, 6H, CH3); 
13
C NMR 
(CDCl3) δ (ppm.): 171.3 (C-S), 165.6 (C=N), 115.1, 119.0, 119.6, 125.4, 126.5, 128.3, 130.5, 
130.8, 133.2, 137.4, 148.2, 152.1 (aromatic-C), 34.3 (CH2), 19.5 (CH3).
119
Sn NMR (DMSO-
d6) δ (ppm.): -441. 
2.2.2.5. Tin(IV) [S-4-methybenzyl-β-N-(2,3-dihydroxybenzylmethylene) 
dithiocarbazate] (5) 
 Orange powder. Yield: 83%. Melting point: 206-209 °C. Analysis calculated for 
C32H28N4O4S4Sn: C, 49.30; H, 3.62; N, 7.19%. Found: C, 49.02; H, 3.16; N, 7.85%. FT-IR 
(ATR, cm
-1
): 1620, v(C=N); 1006, v(N-N); 965, v(C-S). 
1
H NMR (DMSO-d6) δ (ppm.): 8.65, 
(s, 2H, CH), 6.50-7.35 (multiplet, 14H, Ar-H), 4.41 (s, 4H, CH2), 2.29 (s, 6H, CH3); 
13
C 
NMR (DMSO-d6) δ (ppm.): 150.8 (C-S), 145.2 (C=N); 118.4, 129.5, 129.6, 134.2, 136.8 
(aromatic-C), 21.2 (CH3), 37.8 (CH2).
119
Sn NMR (DMSO-d6) δ (ppm.): -443. 
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2.2.2.6. Tin(IV) [S-benzyl-β-N-(2,3-dihydroxy-benzylmethylene)dithiocarbazate] (6) 
 Orange powder. Yield: 67%. Melting point: 206-208 °C. Analysis calculated for 
C30H24N4O4S4Sn: C, 47.95; H, 3.22; N, 6.46%. Found: C, 47.72; H, 2.93; N, 6.25%. FT-IR 
(ATR, cm
-1
): 1612, v(C=N); 1016, v(N-N); 960, v(C-S). 
1
H NMR (DMSO-d6) δ (ppm.): 8.60, 
(s, 2H, CH), 6.27-7.41 (multiplet, 16H, Ar-H), 4.44 (s, 4H, CH2); 
13
C NMR (DMSO-d6) δ 
(ppm.): 155.9 (C-S), 153.4 (C=N); 111.6, 114.3, 115.9, 116.9, 127.5, 128.9, 129.7, 137.6, 
146.9 (aromatic-C), 38.1 (CH2).
119
Sn NMR (DMSO-d6) δ (ppm.): -462. 
 
2.3 Single crystal X-ray structure determination 
An Oxford Diffraction Gemini Eos CCD diffractometer fitted with Mo Kα radiation ( = 
0.71073 Å) was employed to measure intensity data for the orange crystals of 2 and 3 at T = 
150 K.  The data reduction and analytical absorption corrections were accomplished with 
CrysAlisPro [38].  The structures were solved by direct-methods [39] and refined (anisotropic 
displacement parameters, C-bound H atoms in the riding model approximation) on F
2
 [40].  
A weighting scheme w = 1/[σ 2(Fo
2
) + (aP)
2
 + bP] where P = (Fo
2
 + 2Fc
2
)/3) was introduced 
in each case.  In the final cycles of the refinement of 2, a reflection, i.e. (-6 -4 8), was omitted 
owing to poor agreement.  The molecular structure diagrams was generated with ORTEP for 
Windows [41] with 50% displacement ellipsoids and the packing diagrams were drawn with 
DIAMOND [42].  Additional data analysis was made with PLATON [43].  Crystal data and 
refinement details are given in Table 1. 
 
2.4 Computational calculations 
DFT calculations were performed as reported previously from our group [36]. 
 
2.5 In vitro cytotoxic activity 
The cytotoxicity of tin(IV) compounds against HT29 (colon), U87 and SJ-G2 (glioblastoma), 
MCF-7 (breast), A2780 (ovarian), H460 (lung), A431 (skin), Du145 (prostate), BE2-C 
(neuroblastoma), MIA (pancreas) cell lines and one normal breast cell line, MCF-10A 
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(normal breast) were performed by MTT assay using the same method reported by Yusof et 
al [36]. 
 
Table 1  
Crystal data and refinement details for complexes 2 and 3. 
Complex 2 3 
Formula C34H32N4O4S4Sn C32H28N4O4S4Sn 
Formula weight 807.56 779.51 
Crystal system Monoclinic Monoclinic 
Space group P21/n P21/c 
a/Å 12.8540(2) 12.8656(3) 
b/Å 19.4686(5) 8.4693(2) 
c/Å 27.2466(6) 29.8639(7) 
/° 101.109(2) 96.634(2) 
V/Å
3
 6690.7(3) 3232.26(13) 
Z 8 4 
Dc/g cm
-3
 1.603 1.602 
F(000) 3280 1576 
(MoK)/mm-1 1.059 1.093 
Measured data 44247 36728 
 range/° 3.3 – 25.2 3.4 – 25.2 
Unique data 15972 7934 
Observed data (I  2.0(I)) 10737 6324 
No. parameters 855 408 
R, obs. data; all data 0.041; 0.079 0.035; 0.072 
a; b in weighting scheme 0.036; 1.389 0.032; 2.061 
Rw, obs. data; all data 0.076; 0.093 0.052; 0.080 
GoF 1.05 1.02 
Range of residual electron 
density peaks/eÅ
-3
 -0.75 – 0.91 -0.57 – 0.50 
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3.  Results and discussion 
3.1 Synthesis 
Six new homoleptic tin(IV) compounds were synthesised by the condensation reaction of S-
substituted dithiocarbazate Schiff bases of 2-hydroxy-3-methoxybenzaldehyde or 2,3-
dihydroxybenzaldehyde with tin(II) chloride (Scheme 1), whereby the tin(II) precursor 
underwent oxidation to tin(IV) after reflux for 6 hours [44]. The tin(IV) compounds were 
stable at room temperature and soluble in most organic solvents, especially dimethylsulfoxide 
(DMSO) and dimethylformamide (DMF), except 2 which was not soluble in DMSO. Due to 
the insolubility of 2, cytotoxic activity was not determined. The molar conductance of 10
-3 
M 
solutions of synthesised compounds in DMSO were in the range 1.12-6.07 Ω-1 cm2 mol-1, 
indicating their non-electrolytic nature [45]. 
 
R
S N
H
S
N
HO
R'
R
S N
S
N
O
R'
R
SN
S
N
O
R' Sn
Et3N, EtOH
reflux (6 hours)
Where: R = o-CH3, R' = O-CH3  (1)
             R = p-CH3, R' = O-CH3  (2)
             R = H, R' = O-CH3         (3)
             R = o-CH3, R' = OH       (4)
             R = p-CH3, R' = OH       (5)
             R = H, R' = O-H             (6)
SnCl2
 
Scheme 1: Synthetic pathway for the synthesis of 1-6. 
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3.2 Infrared spectra analysis 
The infrared spectra of 1-6 were measured in the range of 4000 to 280 cm
−1
 and verified 
using frequencies predicted using DFT. Complete experimental and calculated IR data are 
provided in Supplementary Information, Table S1. In the experimental IR spectra of Schiff 
bases (H2L1-6), the vibration bands of v(o-O-H), v(NH), v(C=N), v(N-N) and v(C-S) were 
observed in the range of 3488-3501, 3084-3106, 1598-1608, 1114-1125 and 1012-1030 cm
-1
, 
respectively. However, the v(O-H) of H2L1, H2L2 and H2L3 were not observed in the IR 
spectra due to the intra- and inter-molecular interactions between the molecules, which was 
similar to that reported in our previous work [36]. The disappearance of the v(N-H) band for 
all Schiff bases and the v(O-H) band for H2L4, H2L5 and H2L6 indicate the deprotonation of 
N-H and O-H groups and its subsequent coordination to the central tin atom. The shifting of 
v(C=N) band observed in the spectra of tin(IV) compounds proves that the complexation 
occurred through the azomethine nitrogen. The IR group assignments for the experimental 
and theoretical calculation in gas phase appeared in good agreement with experimental data, 
shown in Fig. S1.  
 
3.3 Multinuclear (
1
H, 
13
C and 
119
Sn) NMR spectral analysis 
The important signals observed in the range of 9.51-9.61 ppm and 13.32-13.41 ppm were 
assigned to the proton of -OH and -NH in the Schiff base, respectively, which were reported 
in our previous publications [36]. Both of the signals disappeared in the 
1
H NMR of the 
tin(IV) compounds indicating the deprotonation of the -OH and -NH groups upon 
complexation. This confirmed the coordination of the oxygen and nitrogen donor atom of 
Schiff bases to the tin ion. Moreover, the signal of the HC=N proton in the spectra of tin(IV) 
compounds shifted to the downfield region due to the coordination of –NH to tin atom, which 
was a result of the formation of the C=N-N=C conjugated systems [46]. The downfield shift 
of the HC=N signal in the 
13
C NMR spectra, due to electron density transfer from the Schiff 
bases to the acceptor (Sn atom), was consistent with that observed in earlier reports [47,48]. 
Furthermore, the signal attributable to the C–S moiety in the 13C NMR spectra of the tin(IV) 
compounds was shifted upfield compared to their Schiff bases, suggesting coordination of the 
sulphur atom to the tin centre. These observations supported the FTIR analysis noted above. 
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All the data obtained in the 
1
H NMR and 
13
C NMR spectra are listed in Tables S2 and S3, 
respectively. 
The geometry of compounds 1-6 was verified further via 
119
Sn NMR spectroscopy. A sharp 
signal was observed in the range δ -441 to -462 in the 119Sn NMR spectra of compounds 1-6, 
which strongly supported a six-coordinated, distorted octahedral geometry around tin, 
comparable to reported literature [49].  
 
3.4 UV-vis absorption spectral analysis 
The experimental UV-vis spectra of tin(IV) compounds in DMSO showed a prominent 
absorption peak in the range of 343-355 nm, which is attributed to the n→π* and π→π* 
transitions, and showed excellent correlation with the TD-DFT electronic excitations between 
348-353 nm (gas phase). The other experimental absorption peak to take into account ranged 
from 415-427 nm, which indicated the presence of the S→SnIV LMCT band; TD-DFT 
predicted equivalent transitions between 428-438 nm. The HOMO in 1-6 was primarily 
located on the dithiocarbazate backbone, the phenyl ring of the aldehyde moiety, and the 
oxygen atom coordinated to central tin. The LUMO centred on the dithiocarbazate backbone 
and phenyl ring of aldehyde. Analysis of these frontier MO’s (Fig. 1) supported the 
hypothesis that the n→π* transition occurred due to the presence of the electron lone-pairs in 
the azomethine nitrogen, thiolate sulphur and phenoxide oxygen atoms. The π→π* transition 
observed in all tin(IV) compounds corresponded to the electron delocalisation around the 
aromatic rings. Complete transitions are tabulated in Table S4. 
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Fig. 1. Frontier MOs of (a) 1, (b) 2, (c) 3, (d) 4, (e) 5 and (f) 6. 
 
3.5 X-ray crystallography 
Crystal structure determinations were achieved for each of the homoleptic compounds 2 and 
3; selected geometric parameters are collected in Table S5.  The crystallographic asymmetric 
unit of 2 comprises two independent molecules with the first shown in Fig. 2(a) and the 
second molecule shown in Fig. S2.  For 3, one molecule comprises the asymmetric unit, Fig. 
2(b).  For the first independent molecule of 2, the dinegative tridentate ligand coordinates the 
tin atom via thiolate-S, phenoxide-O and imine-N atoms to establish five-membered 
Sn,S,C,N2 and six-membered Sn,O,C3,N rings.  Evidence for the presence of thiolate-sulphur 
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atoms is found in the elongation of the C1−S1 and C18−S3 bond lengths (Table S5) from 
1.670(2) Å, which is found in the most closely related acid molecule for which a 
crystallographic analysis has been reported, i.e. the benzyl ester rather than the 4-tolylCH2 
ester [37].  Concomitantly, the C1−N1 and C18−N3 bond lengths (Table S5) have decreased 
considerably from 1.338(2) Å in the acid [37]. The conformation of the two tridentate ligands 
is such that all like atoms are mutually trans in a distorted octahedral environment.  The 
major distortions from the ideal octahedral geometries are due to the acute chelate angles in 
the five-membered rings, i.e. 78.88(7)° for S1−Sn−N2 and 78.94(7)° for the S3−Sn−N4 
angle. 
The S1-five-membered chelate ring formed by the tridentate ligand is strictly planar with the 
RMSD of the fitted atoms being 0.0036 Å.  However, the S3-ring is less planar with the 
RMSD being 0.0629 Å.  A better description for the latter is an envelope in which the tin 
atom lies 0.308(4) Å out of the least-squares plane defined by the remaining four atoms 
(RMSD = 0.0060 Å).  Envelope conformations also apply for the six-membered chelate 
rings.  For the O1-ring, the tin atom lies 0.579(4) Å out the plane through the five remaining 
atoms.  For the O3-ring the envelope is somewhat flattened with the tin atom 0.135(4) Å out 
of the plane (RMSD = 0.0234 Å), see Table S6.  The dihedral angle between the five-
membered chelate rings is 81.56(8)°. 
As seen from the overlay diagram in Fig. 2(c), there are conformational differences between 
the independent molecules of 2, at least with respect to the terminal thioester residues.  The 
data in Table S5 and Table S6 confirm the close similarity between the independent 
molecules in terms of the tin-atom geometries. 
The trends in the structure of 3 follow those established for 2, with the most obvious 
difference relating to the coordination of the imine-N2 and N4 atoms.  The angle they 
subtend at the tin atom is wider by ca 6-7°, and there is evidence to suggest the Sn–N2, N4 
bond lengths are marginally shorter than the equivalent bonds in the molecules of 2.  Each of 
the chelate rings adopts an envelope conformation with data presented in Table S6.  The 
dihedral angle between the five-membered chelate rings in 3 is 81.77(5)°, i.e. within 
experimental error of the value computed for 2. 
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Fig. 2. Molecular structures of the molecules in (a) 2 (first independent molecule; the 
structure for the second independent molecule is shown in Fig. S2) and (b) 3, showing atom 
labelling schemes and 50% displacement ellipsoids.  (c) Overlay diagram of the molecules in 
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2 (red image for the first independent molecule), 2a (green, inverted second molecule) and 3 
(blue).  Molecules have been overlapped so the Sn,S1,N2 chelate rings are coincident. 
 
There are three related homoleptic tin(IV) compounds that have been structurally 
characterised in the literature, namely the ethyl thioester and unsubstituted phenoxide residue 
[50], benzyl thioester, unsubstituted phenoxide residue and methyl bound to the imine-carbon 
[51] and benzyl thioester with a ferrocenyl substituent adjacent to the alkoxide-oxygen atom 
[44].  The contrasting and curious feature of the literature structures is that the thiolate-
sulphur atoms are mutually cis, as are the alkoxide-oxygen atoms.  The reasons for the 
different conformations observed in 2 and 3, and those in the literature remain unclear. 
In the absence of conventional hydrogen bonding, the crystals of 2 and 3 are sustained by a 
variety of other non-covalent interactions; the geometric parameters characterising these are 
included in the captions to the respective figures in the Tables 2 and 3.  In the molecular 
packing of 2, each of the independent molecules form equivalent intermolecular contacts with 
the other independent molecule to sustain a supramolecular layer in the ab-plane.  These are 
imine-C2-H
…
S3(thiolate), imine-C19-H
…
S1(thiolate), methoxybenzene-C7-H
…
O2(methoxy), 
methoxybenzene-C24-H
…O4(methoxy) and π(C3-C8)…π(C20-C25). The connections 
between layers along the c-axis direction are of the type methyl-C16a-H
…
O2a, methyl-C16-
H
…π(C10-C15) and methoxy-C34-H…π(C10-C15).  These occur between like-molecules and 
hence, differentiate the independent molecules comprising the asymmetric unit in terms of 
their supramolecular association.  Images of the supramolecular association operating in the 
crystal of 2 are shown in Fig. S3. 
As seen in Fig. S4, supramolecular layers in the ab-plane are also formed in the crystal of 3 
via a combination of methoxybenzene-C7–H…O4(methoxy), methoxybenzene-C23–
H
…
O2(methoxy), methylene-C25–H…S1(thiolate), methoxy-C16–H…π(C10-C15) and π(C3-
C8)
…π(C3…C8) interactions.  Layers inter-digitate along the c-axis direction but, without 
directional interactions between them. Geometric parameters characterising intermolecular 
interactions in the crystal of 3 are given in Table 3. 
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Table 2 
Geometric parameters (Å, °) characterising intermolecular interactions in the crystal of 2. 
A H B H
…
B A
…
B A–H…B Symmetry operation 
C2 H2 S3a 2.81 3.721(3) 162 -1+x, y, z 
C2A H2a S3 2.81 3.628(3) 145 1+x, y, z 
C7 H7 O2a 2.49 3.421(4) 166 ½-x, -½+y, ½-z 
C7a H7a O2 2.49 3.267(4) 139 1½-x, ½+y, ½-z 
C16a H16f O2a 2.56 3.425(4) 147 -1+x, y, z 
C19 H19 S1a 2.72 3.564(3) 148 x, y, z 
C19a H19a S1 2.77 3.699(3) 166 x, y, z 
C24 H24 O4a 2.45 3.267(4) 144 1½-x, -½+y, ½-z 
C24a H24a O4 2.53 3.464(3) 169 ½-x, ½+y, ½-z 
C16 H16b Cg(C10-C15) 2.85 3.533(4) 127 -x, -y, -z 
C34 H34b Cg(C10-C15) 2.84 3.609(4) 136 -x, -y, -z 
Cg(C3-C8) Cg(C20a-C25a)  3.4564(19)  ½-x, -½+y, ½-z 
Cg(C20-C25) Cg(C3a-C8a)  3.5716(19)  1½-x, -½+y, ½-z 
 
Table 3 
Geometric parameters (Å, °) characterising intermolecular interactions in the crystal of 3. 
 
A H B H
…
B A
…
B A–H…B Symmetry operation 
C7 H7 O4 2.60 3.487(3) 156 1-x, -y, 2-z 
C23 H23 O2 2.37 3.140(3) 138 2-x, -y, 2-z 
C25 H25b S1 2.79 3.645(3) 145 2-x, 1-y, 2-z 
C16 H16a Cg(C10-C15) 2.95 3.354(4) 106 1-x, -y, 2-z 
Cg(C3-C8) Cg(C3-C8)  3.5623(15)  1-x, -y, 2-z 
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3.6 In vitro cytotoxic activity 
The cytotoxic assay of 1, 3, 4, 5 and 6 were carried out against a panel ten of cancer cell lines 
and one normal cancer cell line. All the compounds, except compound 2 used in this work 
were insoluble in water. However, they were very soluble in DMSO, and the presence of 1% 
DMSO proved sufficient for their dissolution in aqueous media for cytotoxicity test. The 
stability of the compounds was analysed by monitoring the electronic spectra of the 
compounds in DMSO as well as DMSO-H2O (1:99) over 72 h at room temperature, and an 
unchanged pattern in the spectra was indicative that the compounds were stable in both the 
solvent systems tested. We were unable to determine the cytotoxicity of 2 due to its 
insolubility in 100% DMSO at 1 mM. Cisplatin (standard drug) was used as a positive control 
and DMSO was used as the negative control. Table 4 shows that the cytotoxicity of the 
tin(IV) compounds and their respective Schiff bases. 1, 3, 4, 5 and 6 exhibited moderate 
activity against all the tested cancer cell lines. The cytotoxicities of these compounds against 
HT29, MCF7 and MIA were higher than cisplatin. With respect to the cytotoxicity of the 
precursor Schiff bases, 1, 2, 5 and 6 were equipotent to their corresponding Schiff bases, with 
the exception of 4. Compound 4 demonstrated higher potency than their corresponding Schiff 
bases against HT29, U87, MCF-7, A431 and Du145 cells. The mechanism of action of 4 is 
worthy of further in-depth investigation. In general, for compounds 1, 2, 5 and 6, it can be 
inferred that the presence of tin does not influence cytotoxicity. This is possibly due to the 
bulkiness of the compound and only the coordinated Schiff bases playing a role in binding to 
macromolecules [52].  
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Table 4  
Summary of the in vitro cytotoxicity of tin(IV) compounds in several cell lines, determined by the MTT assay and expressed as a GI50 value with 
standard error. GI50 is the concentration of tin(IV) compounds at which cell growth is inhibited at 50% over 72 hours. 
 
 
(The compounds H2L1, H2L2 and H2L3 published as S2MoVaH, S4MoVaH, SBoVaH, respectively in ref [36]) 
 
GI50 (μM): (the colors indicate) = 0.1 – 0.99; = 1.0 – 9.9; = 10 - 100; = nd (not determined) 
Compounds 
Growth inhibition concentration, GI50 (µM) 
HT29 U87 MCF-7 A2780 H460 A431 Du145 BE2-C SJ-G2 MIA MCF10A 
H2L1 3.9 ± 0.71 4.3 ± 0.30 2.7 ± 0.21 3.2 ± 0.15 4.3 ± 0.12 3.8 ± 0.033 4.1 ± 0.09 3.1 ± 0.00 3.0 ± 0.09 4.9 ± 0.37 3.1 ± 0.07 
1 3.9 ± 0.53 4.2 ± 0.03 2.9 ± 0.07 3.3 ± 0.10 4.0 ± 0.09 3.8 ± 0.15 4.6 ± 0.17 3.0 ± 0.13 2.9 ± 0.12 4.2 ± 0.27 3.2 ± 0.21 
H2L2 8.0 ± 3.5 3.9 ± 0.00 3.5 ± 0.00 3.1 ± 0.40 5.5 ± 0.73 4.2 ± 0.74 5.4 ± 0.23 3.6 ± 0.27 3.3 ± 0.87 11 ± 2.3 3.5 ± 0.23 
2 nd nd nd nd nd nd nd nd nd nd nd 
H2L3 2.2 ± 0.033 3.1 ± 0.26 2.5 ± 0.12 3.0 ± 0.06 3.3 ± 0.21 3.0 ± 0.15 3.4 ± 0.30 2.8 ± 0.20 2.4 ± 0.26 4.5 ± 0.25 3.0 ± 0.067 
3 2.5 ± 0.30 3.1 ± 0.13 2.5 ± 0.23 2.6 ± 0.12 3.0 ± 0.12 2.5 ± 0.32 3.5 ± 0.26 2.1 ± 0.00 1.4 ± 0.36 2.7 ± 0.21 2.8 ± 0.19 
H2L4 10 ± 3.5 20 ± 5.2 10 ± 3.1 1.8 ± 1.2 8.7 ± 1.9 14 ± 1.5 23 ± 3.6 0.38 ± 0.07 6.4 ± 2.2 5.5 ± 1.1 3.7 ± 0.50 
4 4.4 ± 0.83 9.3 ± 1.8 4.4 ± 1.9 2.7 ± 0.20 4.7 ± 0.23 3.7 ± 0.25 6.4 ± 1.4 1.7 ± 0.33 1.9 ± 0.36 4.6 ± 0.97 3.3 ± 0.19 
H2L5 2.8 ± 0.033 4.0 ± 0.43 2.8 ± 0.067 2.8 ± 0.20 3.7 ± 0.10 3.7 ± 0.20 4.2 ± 0.59 3.2 ± 0.30 3.3 ± 0.30 6.6 ± 1.7 2.9 ± 0.033 
5 3.3 ± 0.26 4.8 ± 0.52 3.0 ± 0.15 3.3 ± 0.26 4.2 ± 0.12 3.7 ± 0.32 6.0 ± 0.58 2.7 ± 0.43 3.0 ± 0.27 11 ± 0.88 2.8 ± 0.33 
H2L6 2.1 ± 0.35 2.7 ± 0.47 2.3 ± 0.32 2.2 ± 0.25 2.6 ± 0.27 2.4 ± 0.26 2.8 ± 0.15 2.0 ± 0.23 2.2 ± 0.47 2.2 ± 0.64 2.9 ± 0.21 
6 2.1 ± 0.44 3.3 ± 0.23 2.2 ± 0.20 2.4 ± 0.38 2.1 ± 0.28 2.8 ± 0.23 3.8 ± 0.52 2.1 ± 0.17 1.4 ± 0.23 2.5 ± 0.64 2.8 ± 0.088 
SnCl2 > 25 > 25 > 25 > 25 > 25 > 25 > 25 > 25 > 25 > 25 > 25 
Cisplatin 11.0 ± 2.0 4.0 ± 1.0 6.5 ± 0.8 1.0 ± 0.1 0.9 ± 0.2 2.4 ± 0.3 1.2 ± 0.1 1.9 ± 0.2 0.4 ± 0.1 8.0 ± 1.0 nd 
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4. Conclusions 
Six octahedral tin(IV) compounds were synthesised by the condensation reaction of tin(II) 
chloride with dithiocarbazate Schiff bases. The oxidation of tin(II) to tin(IV) occurred in this 
work as two binegatively charged Schiff bases ONS-bonded to the tin centre with general 
formulae [Sn(Ln)2]. X-ray crystallography indicated that the dinegative tridentate ligands of 2 
and 3 coordinated to the tin atoms via thiolate-S, phenoxide-O and imine-N atoms, leading to 
octahedral geometries in which the like-atoms were mutually trans. The in vitro cytotoxicity 
against a panel of cancer cell lines viz., HT29, U87, SJ-G2, MCF-7, A2780, H460, A431, 
Du145, BE2-C and MIA cancer cell lines revealed that compounds 1, 3, 5 and 6 showed 
moderate cytotoxicity; similar to that of their respective Schiff bases. However, compound 4 
exhibited a higher potency against HT29, U87, MCF-7, A431 and Du145 cells as compared 
to the precursor Schiff base.  
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SUPPLEMENTARY INFORMATION 
Table S1. Experimental and calculated vibrations (cm
-1
) of tin(IV) compounds  
Compound Method 
  IR bands (cm
-1
) 
v(m-OH) v(o-OH) v(NH) v(C=N) v(N-N) v(C-S) 
H2L1 
Experimental -  - 3084 1600 1117 1026 
B3LYP/ 6-311G(d,p) - 3419 3377 1596 1112 1024 
H2L2 
Experimental - - 3092 1598 1118 1030 
B3LYP/ 6-311G(d,p) - 3415 3378 1596 1112 1024 
H2L3 
Experimental - - 3090 1598 1125 1030 
B3LYP/ 6-311G(d,p) - 3419 3377 1596 1112 1025 
H2L4 
Experimental  - 3496 3097 1608 1119 1013 
B3LYP/ 6-311G(d,p) 3712 3368 3359 1597 1112 1025 
H2L5 
Experimental   3501 3106 1607 1114 1012 
B3LYP/ 6-311G(d,p) 3711 3365 3358 1597 1113 1027 
H2L6 
Experimental   3488 3097 1608 1119 1018 
B3LYP/ 6-311G(d,p) 3712 3363 3358 1614 1113 1026 
1 
Experimental - - - 1587 1088 955 
B3LYP/LanL2DZ/6-311G(d,p) - - - 1578 1024 929 
2 
Experimental - - - 1593 1083 958 
B3LYP/LanL2DZ/6-311G(d,p) - - - 1623 1058 967 
3 
Experimental - - - 1582 1031 958 
B3LYP/LanL2DZ/6-311G(d,p) - - - 1619 1056 949 
4 
Experimental 3384 - - 1610 1035 964 
B3LYP/LanL2DZ/6-311G(d,p) 3706 - - 1623 1073 966 
5 
Experimental 3452 - - 1620 1006 965 
B3LYP/LanL2DZ/6-311G(d,p) 3708 - - 1622 1074 962 
6 
Experimental 3033 - - 1612 1016 960 
B3LYP/LanL2DZ/6-311G(d,p) 3707 - - 1628 1074 962 
 Fig. S1. The linear regression between the experimental and theoretical frequencies of 
compounds 1-6. 
 
 
 
Table S2  
1
H NMR spectral data for the tin(IV) compounds 
Compound 
  
1H NMR Assignment, δ (ppm) 
NH OH 
CH CH2 O-CH3 Bz- CH3 Aromatic Protons 
H2 L1 13.34 (s, 1H) 9.57 (s, 1H) 8.51 (s, 1H) 4.40 (s, 2H) 3.76 (s, 3H) 2.30 (s, 3H) 6.75-7.34 (m,7H) 
H2 L2 13.32 (s, 1H) 9.61 (s, 1H) 8.51 (s, 1H) 4.39 (s, 2H) 3.76 (s, 3H) 2.23 (s, 3H) 6.97-9.79 (m,7H) 
H2 L3 13.34 (s, 1H) 9.58 (s, 1H) 8.52 (s, 1H) 4.45 (s, 2H) 3.77 (s, 3H) - 6.77-7.37 (m,8H) 
H2 L4 13.41 (s, 1H) 
9.55 (s, 1H); 
9.51 (s, 1H) 
8.51 (s, 1H) 4.45 (s, 2H) 2.34 (s, 3H) - 6.69-7.39 (m, 7H) 
H2 L5 13.39 (s, 1H) 
9.54 (s, 1H); 
9.53 (s, 1H) 
8.51 (s, 1H) 4.44 (s, 2H) 2.29 (s, 3H) - 6.69-7.30 (m, 7H) 
H2 L6 13.39 (s, 1H) 
9.56 (s, 1H); 
9.53 (s, 1H) 
8.50 (s, 1H) 4.47 (s, 2H) - - 6.67-7.39 (m, 8H) 
1 
- - 8.81, 8.45 (s, 
2H) 
4.47, 4.35 (s, 
4H) 
3.85, 3.57 (s, 
6H) 
2.40, 2.36 (s, 
6H) 
6.77-7.33 (m,14H) 
2 
- - 
8.77 (s, 2H) 4.36 (s, 4H) 3.56 (s, 6H) 2.33 (s, 6H) 6.76-7.24 (m,14H) 
3 
- - 
8.78 (s, 2H) 4.44 (s, 4H) 3.55 (s, 6H) - 6.76-7.36 (m, 16H) 
4 
- - 
8.90 (s, 2H) 4.48 (s, 4H) - 2.42 (s, 6H) 6.02-7.34 (m, 14H) 
5 
- - 
8.65 (s, 2H) 4.41 (s, 4H) - 2.29 (s, 6H) 6.51-7.31 (m, 14H) 
6 
- - 
8.60 (s, 2H) 4.44 (s, 4H) - - 6.27-7.41 (m, 16H 
Table S3 
13
C{
1
H} NMR spectral data for the tin(IV) compounds 
Compound 
13
C{
1
H} NMR Assignment, δ (ppm) 
-C=S/  
-C-S 
C=N O-CH3 -CH2 Bz-CH3 Aromatic carbons 
H2 L1 196.1 148.6 56.4 36.9 19.4 
114.4, 118.8, 120.0, 126.7, 128.2, 130.7, 130.8, 134.4, 137.4, 144.9, 
147.4, 148.6 
H2 L2 196.2 148.6 56.4 38.0 21.2 114.4, 118.8, 120.0, 129.6, 129.7, 134.0, 137.0, 145.0, 147.4, 148.6 
H2 L3 196.1 148.6 56.4 38.1 - 114.4, 118.8, 120.0, 127.8, 129.0, 129.8, 137.3, 144.9, 147.4, 148.6 
H2 L4 195.6 146.5 - 36.9 19.3 
118.1, 118.5, 119.7, 120.0, 126.6, 128.2, 130.7, 130.8, 134.3, 137.3, 
146.2, 146.2 
H2 L5 195.8 146.5 - 38.0 21.2 118.1, 118.4, 119.8, 119.9, 129.6, 129.7, 133.8, 137.0, 146.1, 146.2 
H2 L6 195.6 146.5 - 38.1 - 118.1, 118.4, 119.7, 119.9, 127.7, 129.0, 129.7, 137.1, 146.1 
1 
177.2, 
171.0 
165.4, 
161.7 
55.3, 
56.9 
34.2, 
36.2 
19.4 
115.2, 117.2, 118.4, 119.0, 120.2, 121.9, 126.1, 126.2, 126.4, 126.7, 
127.6, 128.0, 130.4, 130.4, 130.5, 130.6, 133.5, 134.5, 137.2, 137.3, 
147.6, 150.4, 152.0, 156.7 
2 170.8 165.4 56.9 35.5 21.2 117.2, 118.4, 119.0, 126.7, 129.2, 129.4, 133.1, 137.3, 152.0, 156.7 
3 170.7 165.5 56.9 35.7 - 117.2, 118.4, 119.0, 126.7, 127.6, 128.7, 129.3, 136.3, 152.0, 156.7 
4 171.3 165.6 - 34.3 19.5 
115.1, 119.0, 119.6, 125.4, 126.5, 128.3, 130.5, 130.8, 133.2, 137.4, 
148.2, 152.1 
5 152.2  150.8 - 37.8 21.2 115.7, 118.4, 129.5, 129.6, 134.2, 136.8, 145.2 
6 155.9 153.4 - 38.1 - 111.6, 114.3, 115.9, 116.9, 127.5, 128.9, 129.7, 137.6, 146.9 
Table S4 
Experimental and calculated UV-vis absorption data of tin(IV) compounds 
 
Compound 
Wavelength (nm) 
Experimental B3LYP/LanLD2Z/6-311G(d,p) 
1 
 
415 436 
345 348 
2 
 
419 437 
355 361 
3 
 
419 438 
348 353 
4 
 
417 428 
345 352 
5 
 
427 432 
345 352 
6 
 
424 432 
343 351 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S5 
Selected geometric parameters (Å, °) for 2 and 3. 
Compound 2 2a 3 
 (x = 18, y = 19) (x = 18, y = 19) (x = 17, y = 18) 
Parameter 
Sn‒S1 2.4828(8) 2.4871(9) 2.4932(7) 
Sn‒S3 2.4961(9) 2.4898(8) 2.4873(7) 
Sn‒O1 2.025(2) 2.026(2) 2.0304(18) 
Sn‒O3 2.032(2) 2.032(2) 2.0242(18) 
Sn‒N2 2.198(2) 2.189(2) 2.169(2) 
Sn‒N4 2.189(2) 2.196(2) 2.173(2) 
N1‒N2 1.398(3) 1.399(3) 1.395(3) 
C1‒S1 1.753(3) 1.749(3) 1.744(3) 
C1‒S2 1.744(3) 1.743(3) 1.741(3) 
C1‒N1 1.288(4) 1.286(4) 1.289(3) 
C2‒N2 1.299(4) 1.309(4) 1.302(3) 
N3‒N4 1.393(3) 1.396(3) 1.397(3) 
C(x)‒S3 1.744(3) 1.754(3) 1.745(3) 
C(x)‒S4 1.743(3) 1.745(3) 1.751(2) 
C(x)‒N3 1.295(4) 1.289(4) 1.288(3) 
C(y)‒N4 1.307(4) 1.303(4) 1.304(3) 
S1‒Sn‒O1 162.46(6) 165.07(6) 164.51(5) 
S3‒Sn‒O3 164.42(6) 162.30(6) 165.46(5) 
N2‒Sn‒N4 170.18(10) 170.45(9) 177.76(8) 
 
 
Table S6 
Least-squares plane data for 2a and 3. 
2a 
S1a-chelate ring: envelope with Sn1a lying 0.307(4) Å above the remaining atoms (RMSD = 
0.0060 Å) 
S3a-chelate ring: planar with RMSD = 0.0057 Å 
O1a-chelate ring: envelope with Sn1a lying 0.579(4) Å above the remaining atoms (RMSD = 
0.0279 Å) 
O3a-chelate ring: envelope with Sn1a lying 0.135(4) Å above the remaining atoms (RMSD = 
0.0234 Å) 
 
3 
S1-chelate ring: envelope with Sn1a lying 0.392(4) Å above the remaining atoms (RMSD = 
0.0066 Å) 
S3-chelate ring: envelope with Sn1a lying 0.309(4) Å above the remaining atoms (RMSD = 
0.0124 Å) 
O1-chelate ring: envelope with Sn1a lying 0.463(4) Å above the remaining atoms (RMSD = 
0.0392 Å) 
O3-chelate ring: envelope with Sn1a lying 0.271(4) Å above the remaining atoms (RMSD = 
0.0343 Å) 
 
 
 
 
Fig. S2.  The molecular structure of the second independent molecule of 2, i.e. 2a, showing 
atom labelling scheme and 50% displacement ellipsoids. 
  
 Fig. S3.  Molecular packing in 2: (a) a side-on view of the supramolecular layer in the ab-
plane, (b) plane view of the supramolecular layer (non-participating hydrogen atoms have 
been removed for clarity) and (c) unit cell contents in projection down the a-axis.  The C–
H
…
O, C–H…S, C–H…π and π…π interactions are shown as orange, green, purple and blue 
dashed lines, respectively. 
 Fig. S4.  Molecular packing in 3: (a) a side-on view of the supramolecular layer in the ab-
plane, (b) plane view of the supramolecular layer (non-participating hydrogen atoms have 
been removed for clarity) and (c) unit cell contents in projection down the b-axis.  The C–
H
…
O, C–H…S, C–H…π and π…π interactions are shown as orange, green, purple and blue 
dashed lines, respectively.  
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Experimental FTIR spectra of tin(IV) compounds 
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Simulated FTIR spectra of tin(IV) compounds 
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Experimental UV-vis spectra of 1. 
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Experimental UV-vis spectra of 2. 
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Experimental UV-vis spectra of 3. 
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Experimental UV-vis spectra of 4. 
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Experimental UV-vis spectra of 5. 
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Experimental UV-vis spectra of 6. 
 
 
Simulated UV-vis spectra of 1. 
 
 
 
Simulated UV-vis spectra of 2. 
 
 
 
Simulated UV-vis spectra of 3. 
 
 
Simulated UV-vis spectra of 4. 
 
 
 
Simulated UV-vis spectra of 5. 
 
 
 
Simulated UV-vis spectra of 6. 
 
checkCIF/PLATON report 
Structure factors have been supplied for datablock(s) shelx
THIS REPORT IS FOR GUIDANCE ONLY. IF USED AS PART OF A REVIEW PROCEDURE
FOR PUBLICATION, IT SHOULD NOT REPLACE THE EXPERTISE OF AN EXPERIENCED
CRYSTALLOGRAPHIC REFEREE.
No syntax errors found.        CIF dictionary        Interpreting this report
Datablock: shelx 
Bond precision: C-C = 0.0047 A Wavelength=0.71073
Cell: a=12.8540(2) b=19.4686(5) c=27.2466(6)
alpha=90 beta=101.109(2) gamma=90
Temperature: 150 K
Calculated Reported
Volume 6690.7(3) 6690.7(3)
Space group P 21/n P 21/n 
Hall group -P 2yn -P 2yn 
Moiety formula C34 H32 N4 O4 S4 Sn C34 H32 N4 O4 S4 Sn
Sum formula C34 H32 N4 O4 S4 Sn C34 H32 N4 O4 S4 Sn
Mr 807.59 807.56
Dx,g cm-3 1.604 1.603
Z 8 8
Mu (mm-1) 1.059 1.059
F000 3280.0 3280.0
F000’ 3279.77
h,k,lmax 17,26,37 17,26,35
Nref 18644 15972 
Tmin,Tmax 0.898,0.948 0.830,1.000
Tmin’ 0.881
Correction method= # Reported T Limits: Tmin=0.830 Tmax=1.000
AbsCorr = MULTI-SCAN
Data completeness= 0.857 Theta(max)= 29.506
R(reflections)= 0.0406( 10737) wR2(reflections)= 0.0932( 15972)
S = 1.005 Npar= 855
checkcif 2
Click here to download Supplementary Material: 2_checkcif.pdf
The following ALERTS were generated. Each ALERT has the format
       test-name_ALERT_alert-type_alert-level.
Click on the hyperlinks for more details of the test.
 Alert level B
PLAT910_ALERT_3_B Missing # of FCF Reflection(s) Below Theta(Min).         31 Note
Author Response: he theta range for the data collection was 3.3 to 29.5
deg., presumably established by CrysAlis PRO. While theta(min) is a little
high, the exclusion of these data is unlikely to be detrimental to the model.
 Alert level C
PLAT220_ALERT_2_C Non-Solvent  Resd 1  C   Ueq(max)/Ueq(min) Range        4.2 Ratio 
PLAT220_ALERT_2_C Non-Solvent  Resd 2  C   Ueq(max)/Ueq(min) Range        3.2 Ratio 
PLAT222_ALERT_3_C Non-Solv.  Resd 1  H   Uiso(max)/Uiso(min) Range        4.4 Ratio 
PLAT906_ALERT_3_C Large K Value in the Analysis of Variance ......      4.485 Check 
 Alert level G
PLAT720_ALERT_4_G Number of Unusual/Non-Standard Labels ..........          2 Note  
PLAT794_ALERT_5_G Tentative Bond Valency for Sn1       (IV)      .       4.25 Info  
PLAT794_ALERT_5_G Tentative Bond Valency for Sn1A      (IV)      .       4.26 Info  
PLAT912_ALERT_4_G Missing # of FCF Reflections Above STh/L=  0.600       2547 Note  
PLAT952_ALERT_5_G Calculated (ThMax) and CIF-Reported Lmax Differ           2 Units 
PLAT958_ALERT_1_G Calculated (ThMax) and Actual (FCF) Lmax Differ           2 Units 
PLAT978_ALERT_2_G Number C-C Bonds with Positive Residual Density.          3 Info  
   0 ALERT level A = Most likely a serious problem - resolve or explain
   1 ALERT level B = A potentially serious problem, consider carefully
   4 ALERT level C = Check. Ensure it is not caused by an omission or oversight
   7 ALERT level G = General information/check it is not something unexpected
   1 ALERT type 1 CIF construction/syntax error, inconsistent or missing data
   3 ALERT type 2 Indicator that the structure model may be wrong or deficient
   3 ALERT type 3 Indicator that the structure quality may be low
   2 ALERT type 4 Improvement, methodology, query or suggestion
   3 ALERT type 5 Informative message, check
It is advisable to attempt to resolve as many as possible of the alerts in all categories. Often the
minor alerts point to easily fixed oversights, errors and omissions in your CIF or refinement
strategy, so attention to these fine details can be worthwhile. In order to resolve some of the more
serious problems it may be necessary to carry out additional measurements or structure
refinements. However, the purpose of your study may justify the reported deviations and the more
serious of these should normally be commented upon in the discussion or experimental section of a
paper or in the "special_details" fields of the CIF. checkCIF was carefully designed to identify
outliers and unusual parameters, but every test has its limitations and alerts that are not important
in a particular case may appear. Conversely, the absence of alerts does not guarantee there are no
aspects of the results needing attention. It is up to the individual to critically assess their own
results and, if necessary, seek expert advice.
Publication of your CIF in IUCr journals 
A basic structural check has been run on your CIF. These basic checks will be run on all CIFs
submitted for publication in IUCr journals (Acta Crystallographica, Journal of Applied 
Crystallography, Journal of Synchrotron Radiation); however, if you intend to submit to Acta
Crystallographica Section C or E or IUCrData, you should make sure that full publication checks
are run on the final version of your CIF prior to submission.
Publication of your CIF in other journals 
Please refer to the Notes for Authors of the relevant journal for any special instructions relating to
CIF submission.
PLATON version of 03/05/2019; check.def file version of 29/04/2019 
Datablock shelx - ellipsoid plot
checkCIF/PLATON report 
Structure factors have been supplied for datablock(s) shelx
THIS REPORT IS FOR GUIDANCE ONLY. IF USED AS PART OF A REVIEW PROCEDURE
FOR PUBLICATION, IT SHOULD NOT REPLACE THE EXPERTISE OF AN EXPERIENCED
CRYSTALLOGRAPHIC REFEREE.
No syntax errors found.        CIF dictionary        Interpreting this report
Datablock: shelx 
Bond precision: C-C = 0.0043 A Wavelength=0.71073
Cell: a=12.8656(3) b=8.4693(2) c=29.8639(7)
alpha=90 beta=96.634(2) gamma=90
Temperature: 150 K
Calculated Reported
Volume 3232.26(13) 3232.26(13)
Space group P 21/c P 21/c 
Hall group -P 2ybc -P 2ybc 
Moiety formula C32 H28 N4 O4 S4 Sn C32 H28 N4 O4 S4 Sn
Sum formula C32 H28 N4 O4 S4 Sn C32 H28 N4 O4 S4 Sn
Mr 779.53 779.51
Dx,g cm-3 1.602 1.602
Z 4 4
Mu (mm-1) 1.093 1.093
F000 1576.0 1576.0
F000’ 1575.87
h,k,lmax 17,11,41 17,11,39
Nref 8947 7934 
Tmin,Tmax 0.827,0.926 0.833,1.000
Tmin’ 0.786
Correction method= # Reported T Limits: Tmin=0.833 Tmax=1.000
AbsCorr = MULTI-SCAN
Data completeness= 0.887 Theta(max)= 29.421
R(reflections)= 0.0348( 6324) wR2(reflections)= 0.0795( 7934)
S = 1.024 Npar= 408
checkcif 3
Click here to download Supplementary Material: 3_checkcif.pdf
The following ALERTS were generated. Each ALERT has the format
       test-name_ALERT_alert-type_alert-level.
Click on the hyperlinks for more details of the test.
 Alert level B
PLAT910_ALERT_3_B Missing # of FCF Reflection(s) Below Theta(Min).         17 Note
Author Response: he theta range for the data collection was 3.4 to 29.4
deg., presumably established by CrysAlis PRO. While theta(min) is a little
high, the exclusion of these data is unlikely to be detrimental to the model.
 Alert level C
PLAT220_ALERT_2_C Non-Solvent  Resd 1  C   Ueq(max)/Ueq(min) Range        3.4 Ratio 
PLAT906_ALERT_3_C Large K Value in the Analysis of Variance ......      2.240 Check 
 Alert level G
PLAT232_ALERT_2_G Hirshfeld Test Diff (M-X)  Sn       --S1       .        5.8 s.u.  
PLAT794_ALERT_5_G Tentative Bond Valency for Sn        (IV)      .       4.34 Info  
PLAT912_ALERT_4_G Missing # of FCF Reflections Above STh/L=  0.600        969 Note  
PLAT952_ALERT_5_G Calculated (ThMax) and CIF-Reported Lmax Differ           2 Units 
PLAT958_ALERT_1_G Calculated (ThMax) and Actual (FCF) Lmax Differ           2 Units 
PLAT978_ALERT_2_G Number C-C Bonds with Positive Residual Density.          5 Info  
   0 ALERT level A = Most likely a serious problem - resolve or explain
   1 ALERT level B = A potentially serious problem, consider carefully
   2 ALERT level C = Check. Ensure it is not caused by an omission or oversight
   6 ALERT level G = General information/check it is not something unexpected
   1 ALERT type 1 CIF construction/syntax error, inconsistent or missing data
   3 ALERT type 2 Indicator that the structure model may be wrong or deficient
   2 ALERT type 3 Indicator that the structure quality may be low
   1 ALERT type 4 Improvement, methodology, query or suggestion
   2 ALERT type 5 Informative message, check
It is advisable to attempt to resolve as many as possible of the alerts in all categories. Often the
minor alerts point to easily fixed oversights, errors and omissions in your CIF or refinement
strategy, so attention to these fine details can be worthwhile. In order to resolve some of the more
serious problems it may be necessary to carry out additional measurements or structure
refinements. However, the purpose of your study may justify the reported deviations and the more
serious of these should normally be commented upon in the discussion or experimental section of a
paper or in the "special_details" fields of the CIF. checkCIF was carefully designed to identify
outliers and unusual parameters, but every test has its limitations and alerts that are not important
in a particular case may appear. Conversely, the absence of alerts does not guarantee there are no
aspects of the results needing attention. It is up to the individual to critically assess their own
results and, if necessary, seek expert advice.
Publication of your CIF in IUCr journals 
A basic structural check has been run on your CIF. These basic checks will be run on all CIFs
submitted for publication in IUCr journals (Acta Crystallographica, Journal of Applied 
Crystallography, Journal of Synchrotron Radiation); however, if you intend to submit to Acta
Crystallographica Section C or E or IUCrData, you should make sure that full publication checks
are run on the final version of your CIF prior to submission.
Publication of your CIF in other journals 
Please refer to the Notes for Authors of the relevant journal for any special instructions relating to
CIF submission.
PLATON version of 03/05/2019; check.def file version of 29/04/2019 
Datablock shelx - ellipsoid plot
Edward Tiekink <edward.tiekink@gmail.com>
CCDC Depository Request
1 message
CCDC Deposit <deposit_reply@ccdc.cam.ac.uk> 16 May 2019 at 07:52
To: Edward Tiekink <edward.tiekink@gmail.com>
Dear Depositor,
Thank you for depositing your crystal structure(s) via the joint CCDC/FIZ Karlsruhe deposition service.
The data have been assigned the following deposition numbers which can either be quoted as CCDC Numbers or
CSD Numbers. A CCDC Number is usually quoted for an organic or metal-organic structure, whereas a CSD Number
is usually quoted for an inorganic structure.
CCDC XXXXXXX-YYYYYYY (generally used for organic and metal-organic structures)
CSD XXXXXXX-YYYYYYY (generally used for inorganic structures)
CCDC 1916354-1916355
---------------------------------------------------------------
Summary of Data CCDC 1916354
---------------------------------------------------------------
Compound Name:
Formula: C34 H32 N4 O4 S4 Sn1
Unit Cell Parameters: a 12.8540(2) b 19.4686(5) c 27.2466(6) P21/n
---------------------------------------------------------------
---------------------------------------------------------------
Summary of Data CCDC 1916355
---------------------------------------------------------------
Compound Name:
Formula: C32 H28 N4 O4 S4 Sn1
Unit Cell Parameters: a 12.8656(3) b 8.4693(2) c 29.8639(7) P21/c
---------------------------------------------------------------
After publication your data will be made available through our joint Access Structures service. In addition, organic and
metal-organic experimental structures will be curated into the Cambridge Structural Database and inorganic
experimental structures will be curated into the Inorganic Crystal Structure Database.
If you selected “Publish in a Database” your data will be immediately published through our joint Access Structures
service.
Please note, if any of these structures are not published within one year from today and we cannot contact you to
discuss the matter, then we may publish the data directly through the CSD as a CSD Communication or the ICSD as
an ICSD Communication.
If we have any queries relating to the data then we may contact you later.
Kind Regards,
The CCDC and FIZ Karlsruhe Deposition Teams
Email: deposit@ccdc.cam.ac.uk
The Cambridge Crystallographic Data Centre
https://www.ccdc.cam.ac.uk
Gmail - CCDC Depository Request https://mail.google.com/mail/u/0?ik=6d81f29b47&view=pt&search=all...
1 of 2 16/5/2019, 7:56 AM
CCDC Depository request
Click here to download Supplementary Material: CCDC Depository Request.pdf
For more information about CSD Communications see:
https://www.ccdc.cam.ac.uk/Community/Depositastructure/CSDCommunications/
FIZ Karlsruhe
www.fiz-karlsruhe.de
The CCDC and FIZ Karlsruhe are delighted to be working together on shared deposition and access services for
crystallographic data across all domains of chemistry 
More details can be found in our press release: https://www.ccdc.cam.ac.uk/News/List/2018-07-new-joint-services/
Gmail - CCDC Depository Request https://mail.google.com/mail/u/0?ik=6d81f29b47&view=pt&search=all...
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Scheme 1
Click here to download Mol Files: Scheme1.cdx
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